The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
CPX-351 therapy for less fit patients with untreated AML
In a letter to the Editor of Haematologica, Roland B. Walter [member of the AGP North American Steering Committee] , from the Fred Hutchinson Cancer Research Center, Seattle, WA, and colleagues reported results from a phase II randomized study (NCT01804101), which evaluated attenuated doses of CPX-351, a liposomal formulation of daunorubicin and cytarabine co-encapsulated at a molar ratio of 1:5, in medically less fit patients with untreated AML with a Treatment Related Mortality (TRM) score of > 13.1.
The main objective of this phase II study was to estimate whether 32 units/m2 or 64 units/m2 or both dose levels of CPX-351 could improve TRM rate (versus the historical rate of 30%) while keeping Complete Remission (CR) rate constant in AML patients with high risk of TRM.
In total, 48 patients with a median age of 70.5 years (range, 39.1 –91.1 years) were enrolled in this study between May 2013 and November 2016. Patients were randomized 1:1 to receive either 32 or 64 units /m2 of CPX-351 on Days 1, 3 and 5 for up to four identical induction/re-induction courses. Patients received a median of two (range: 1 – 6) cycles of CPX-351 therapy. Due to the small sample size, randomization was stratified using a dynamic allocation scheme based on TRM score, cytogenetic risk and presence/absence of secondary disease.
Initially, the first 20 patients enrolled in this study were randomized to receive either doses of CPX-351.
Key findings in the 64 units/m2/dose arm (n = 10):
- CR and CR with Incomplete Blood Count Recovery (CRi) was achieved in two patients respectively
- Both patients relapsed (after 27 and 251 days) and died on Day 320 and 364
- Early death occurred in four (40%) patients by Day 28 due to infections with TRM scores of 14.7, 24.1, 33.4, and 58.1 respectively
- Median Overall Survival (OS): 6 months
- Due to early death, accrual in the 64 units/m2/dose arm was terminated
The remaining patients (n = 28) enrolled in this study were administered 32 units/m2 CPX-351
Key findings in the 32 units/m2/dose arm (n = 38):
- CR was achieved in 10 patient
- CRi was achieved in one patient
- Resistant disease was observed in 21 patients
- Early death rate: 28.9% (11/38)
- Six patients died due to indeterminate causes
- Median OS: 3 months
- Median relapse free survival in responders (n = 11): 7 months
In summary, the optimal treatment dosage of CPX-351 for less-fit AML patients remains unidentified. The authors concluded that this study demonstrates that CPX-351 at 32 or 64 units/m2 failed to lower the TRM rate to 15% compared to the historical control while maintaining CR rate of 30% in patients with high-risk of AML.
References